Oncolytic virus therapy with HSV-1 for hematological malignancies
| Project/Area Number |
15K09501
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 造血器腫瘍 / ウイルス療法 / 免疫療法 |
|---|
| Outline of Final Research Achievements |
A recombinant HSV-1, T-01, killed 16 out of 21 human cell lines of hematological malignancies. Positive correlations were observed among the expression levels of HSV-1 receptor nectin-1, entry of T-01, and cytotoxicity. In accord with it, knockdown of nectin-1 decreased entry of T-01, and forced expression of nectin-1 induced cytotoxic activity.
These data indicate that viral entry via nectin-1 is a determining factor of cytotoxicity by oncolytic HSV-1 against hematological malignancies, and that the expression of nectin-1 is a biomarker of the susceptibility of hematological malignancies to HSV-1.
|
| Academic Significance and Societal Importance of the Research Achievements |
がんウイルス療法がさまざまな固形がんに対する免疫療法の1つとして発展しつつあり、中でもHSV-1がメラノーマに対して実用化されている中、このウイルスが造血器腫瘍に対しても有効性が期待できることが示された。このことは、造血器腫瘍に対する免疫療法の選択肢を増やし治療成績の向上につながるとともに、今後ウイルス療法と免疫チェックポイント阻害療法の併用といった複合的免疫療法の開発に発展しうる成果である。
|
Report
(5 results)
Research Products
(24 results)
-
-
-
[Journal Article] Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib2017
Author(s)
Ishiyama K, Kitawaki T, Sugimoto N, Sozu T, Anzai N, Okada M, Nohgawa M, Hatanaka K, Arima N, Ishikawa T, Tabata S, Onaka T, Oka S, Nakabo Y, Amakawa R, Matsui M, Moriguchi T, Takaori-Kondo A, Kadowaki N
-
Journal Title
Leukemia
Volume: 31
Issue: 1
Pages: 203-212
DOI
Related Report
Peer Reviewed
-
[Journal Article] Hypomethylation of the Treg-specific demethylated region in FOXP3 is a hallmark of the regulatory T-cell subtype in adult T-cell leukemia2016
Author(s)
Shimazu Y, Shimazu Y, Hishizawa M, Hamaguchi M, Nagai Y, Sugino N, Fujii S, Kawahara M, Kadowaki N, Nishikawa H, Sakaguchi S, Takaori-Kondo A
-
Journal Title
Cancer Immunol Res
Volume: 4
Issue: 2
Pages: 136-145
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] がん免疫療法の進歩2015
Author(s)
門脇則光
Organizer
第59回日本輸血・細胞治療学会近畿支部総会
Place of Presentation
枚方
Year and Date
2015-10-28
Related Report
Invited
-
-
-
